Research Progress of Antibody Drugs Targeting Epidermal Growth Factor Receptor

Epidermal growth factor receptor (EGFR), as a member of the receptor tyrosine kinase (RTK) protein family, plays a crucial role in cell growth, proliferation, and differentiation. Abnormal expression and mutation of EGFR are closely related to the occurrence and development of head and neck cancer, lung cancer, colorectal cancer, and other cancer types, making it one of the most popular targets for tumor-targeted therapies. Currently, EGFR-targeted drugs mainly include small molecule tyrosine kinase inhibitors (TKIs) and antibodies, but both face the problem of drug resistance. To solve this problem, researchers are not only committed to the development of fourthgeneration EGFR-TKIs, but also actively advance the preclinical and clinical studies of a new generation of antibody drugs, including bispecific antibodies targeting two targets and antibody conjugates. This review is on the research progress of antibody drugs targeting EGFR, aiming to provide reference for the development of a new generation of antibody drugs.